Literature DB >> 9146599

Comparative study of papaverine plus phentolamine versus prostaglandin E1 in erectile dysfunction.

A Bechara1, A Casabé, G Chéliz, S Romano, H Rey, N Fredotovich.   

Abstract

PURPOSE: We compared the efficacy and short-term adverse effects of 1 ml. 30 mg./ml. papaverine plus 0.5 mg./ml. phentolamine versus 1 ml. 30 micrograms./ml. prostaglandin E1 in patients undergoing pharmacological erection testing.
MATERIALS AND METHODS: A total of 60 patients (mean age 58 years) with a history of sexual erectile dysfunction longer than 6 months was randomly classified into 6 groups to be tested 1 week apart with the 2 solutions and with placebo to evaluate erection response and short-term adverse effects.
RESULTS: Of the patients tested with papaverine plus phentolamine 54% responded with erections adequate for penetration, compared to 50% of those tested with prostaglandin E1 (p > 0.05). Prolonged erection occurred in 18% of patients tested with papaverine plus phentolamine and 15% of those tested with prostaglandin E1 (p > 0.05). Pain was reported by 15 and 35% of patients, respectively (p < 0.05).
CONCLUSIONS: One ml. 30 mg./ml. papaverine plus 0.5 mg./ml. phentolamine has the same efficacy and equal prolonged erection rate as 1 ml. 30 micrograms./ml. prostaglandin E1 but the latter agent induces significantly more pain.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9146599

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  3 in total

Review 1.  Erectile dysfunction.

Authors:  Mohit Khera; Irwin Goldstein
Journal:  BMJ Clin Evid       Date:  2011-06-29

Review 2.  A comparative review of the options for treatment of erectile dysfunction: which treatment for which patient?

Authors:  Konstantinos Hatzimouratidis; Dimitrios G Hatzichristou
Journal:  Drugs       Date:  2005       Impact factor: 9.546

Review 3.  Korean Society for Sexual Medicine and Andrology (KSSMA) Guideline on Erectile Dysfunction.

Authors:  Ji Kan Ryu; Kang Su Cho; Su Jin Kim; Kyung Jin Oh; Sung Chul Kam; Kyung Keun Seo; Hong Seok Shin; Soo Woong Kim
Journal:  World J Mens Health       Date:  2013-08-31       Impact factor: 5.400

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.